Getinge AB (publ) (GNGBY) Stock Analysis

Getinge AB (publ) (GNGBY) Healthcare & Pipeline Overview

Getinge AB (publ) provides solutions for operating rooms, intensive-care units, and sterilization departments, with a global presence and focus on acute care, life science, and surgical workflows. The company's diverse product portfolio and extensive distribution network position it as a key player in the medical devices sector.

What Is the Investment Thesis for GNGBY?

Getinge AB (publ) presents a notable research candidate due to its established market position in the medical devices sector and its diversified product portfolio. The company's focus on acute care, life science, and surgical workflows provides exposure to multiple growth areas within healthcare. With a P/E ratio of 24.03 and a dividend yield of 2.43%, Getinge offers a blend of value and income. Ongoing catalysts include increasing demand for healthcare solutions driven by an aging global population and advancements in medical technology. However, potential risks include currency fluctuations and competition from other medical device manufacturers.

Based on FMP financials and quantitative analysis

GNGBY Key Highlights

Market capitalization of $6.57B reflects Getinge's significant presence in the medical device industry.

• Profit margin of 6.5% indicates efficient operations and profitability.
• Gross margin of 45.9% demonstrates the company's ability to maintain pricing power and manage costs.
• Dividend yield of 2.43% provides an income stream for investors.
• Beta of 0.88 suggests lower volatility compared to the overall market.

Who Are GNGBY's Competitors?

GNGBY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are GNGBY's Key Strengths?

Diversified product portfolio

• Global presence and distribution network
• Strong brand reputation
• Focus on innovation

What Are GNGBY's Weaknesses?

Exposure to currency fluctuations

• Dependence on healthcare spending
• Competition from larger medical device companies
• Potential for product recalls

What Could Drive GNGBY Stock Higher?

Increasing demand for healthcare solutions driven by an aging global population.

• Advancements in medical technology and innovation.
• Potential strategic acquisitions to expand product portfolio and market reach.
• Expansion in emerging markets with developing healthcare infrastructure.
• Development of integrated solutions combining hardware, software, and services.

What Are the Key Risks for GNGBY?

Currency fluctuations impacting revenue and profitability.

• Changes in healthcare regulations and reimbursement policies.
• Competition from other medical device manufacturers.
• Product recalls or safety concerns.
• Economic downturns affecting healthcare spending.

What Are the Growth Opportunities for GNGBY?

• Expansion in Emerging Markets: Getinge can leverage its existing distribution network to expand its presence in emerging markets, where healthcare infrastructure is developing and demand for medical devices is increasing. This expansion can drive revenue growth and diversify the company's geographic exposure. The global medical device market is expected to reach $600 billion by 2028, offering significant opportunities for growth.
• Technological Innovation: Investing in research and development to introduce innovative products and solutions can drive growth and maintain a competitive edge. Focus areas include advanced surgical technologies, digital healthcare solutions, and personalized medicine. Continuous innovation will allow Getinge to capture market share and address evolving customer needs. Ongoing investment in R&D is crucial for long-term success.
• Strategic Acquisitions: Acquiring complementary businesses and technologies can expand Getinge's product portfolio and market reach. Strategic acquisitions can provide access to new markets, technologies, and customer segments, accelerating growth and enhancing the company's competitive position. Careful due diligence and integration are essential for successful acquisitions.
• Increased Focus on Life Science Solutions: The life science segment offers significant growth potential due to increasing demand for bioprocessing equipment and solutions. Getinge can capitalize on this trend by expanding its product offerings and strengthening its relationships with pharmaceutical and biotechnology companies. The global bioprocessing market is projected to reach $30 billion by 2027.
• Development of Integrated Solutions: Offering integrated solutions that combine hardware, software, and services can create value for customers and differentiate Getinge from competitors. Integrated solutions can improve efficiency, reduce costs, and enhance patient outcomes. This approach can also create recurring revenue streams through service contracts and software subscriptions.

What Are GNGBY's Competitive Advantages?

• Established brand reputation and long-standing relationships with customers.
• Extensive distribution network and global reach.
• Diversified product portfolio across multiple healthcare segments.
• Strong focus on innovation and research and development.

What Does GNGBY Do?

Founded in 1904 and headquartered in Gothenburg, Sweden, Getinge AB (publ) has evolved into a global provider of medical technology solutions. The company operates through three primary segments: Acute Care Therapies, Life Science, and Surgical Workflows. The Acute Care Therapies segment offers products for critical care, including anesthesia machines, ventilators, and cardiovascular surgery solutions. The Life Science segment provides equipment and systems for sterile transfer, bioprocessing, and laboratory applications. The Surgical Workflows segment focuses on solutions for operating rooms, such as surgical tables, lighting systems, and sterile supply management. Getinge serves a global customer base through a network of proprietary sales companies, agents, and distributors across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Its comprehensive product portfolio and global reach solidify its position as a key player in the healthcare industry.

What Products and Services Does GNGBY Offer?

• Provides equipment for operating rooms and intensive-care units.
• Offers sterilization solutions for healthcare facilities.
• Develops and manufactures bioprocessing systems for the life science industry.
• Provides surgical workflows solutions.
• Offers acute care therapies, including anesthesia and ventilation equipment.
• Provides sterile transfer systems and closure processing systems.

How Does GNGBY Make Money?

• Sells medical devices and equipment to hospitals, clinics, and research institutions.
• Provides service and maintenance contracts for its equipment.
• Offers software solutions for managing surgical workflows and bioprocessing operations.
• Generates revenue through a network of proprietary sales companies, agents, and distributors.

What Industry Does GNGBY Operate In?

Getinge AB (publ) operates in the medical devices industry, which is characterized by continuous innovation and increasing demand driven by an aging global population and rising healthcare expenditures. The industry is competitive, with key players including Abbott Laboratories (ABT), Align Technology (ALGN), and Bio-Rad Laboratories (BIO). Getinge's focus on acute care, life science, and surgical workflows positions it to capitalize on specific growth areas within the broader medical devices market.

Who Are GNGBY's Key Customers?

• Hospitals and clinics
• Research institutions
• Pharmaceutical and biotechnology companies
• Sterilization departments

Getinge AB (publ) Financial Trajectory

Getinge AB (publ) (GNGBY) reported $864.7M in revenue for Q2 FY2026, reflecting 12.6% growth compared to the prior quarter. The company recorded net income of $86.8M, with diluted EPS of $0.32. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, GNGBY averaged $0.25 in diluted EPS.

Company Profile

Getinge AB (publ) operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Gothenburg, SE. The company is led by CEO Mattias Perjos. GNGBY has traded publicly since 2012.

How Getinge AB (publ) Is Valued

Getinge AB (publ) carries a market capitalization of $6.57B, placing it in the mid-cap category.

Return on equity for Getinge AB (publ) stands at 8.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.1%, showing how much profit it generates from its asset base. GNGBY trades at a trailing price-to-earnings ratio of 24.03, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 6.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.35 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.3%, the inverse of the P/E and a quick read on earnings relative to price.

Getinge AB (publ)'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.92 places it in the grey zone, a middle ground that warrants monitoring.

GNGBY Financials

GNGBY Latest News

GNGBY Analyst Consensus

GNGBY MoonshotScore

What Investors Ask About Getinge AB (publ) (GNGBY) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources